NEWS
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has dosed the first patient in Part 2 of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist for obesity treatment. This MAD study, expected to enroll 36 participants, will investigate safety, tolerability, and pharmacokinetics, with top-line data anticipated in Q1 2025. Part 3 of the trial, assessing weight loss and dietary changes over 24 weeks, will begin in Q3 2025, with interim data expected mid-2026. A recent $70 million financing will support the clinical development. Pre-clinical models showed DA-1726's superior weight loss compared to other drugs. The trial aims to establish DA-1726 as a best-in-class obesity treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1091Followers
68Following
7527Visitors
Follow